Therapies in development for community-acquired pneumonia

Bibliography

• KOORNHOF HJ, WASAS A, KLUGMAN K: Antimicrobial resistance in Streptococcus pneurnoniae. a South African perspective. Clin. Infect. Dis. (1992) 15:84–94.
   PubMed Web of Science ®Google Scholar
• KAM KM, LUEY KY, FUNG SM, YIU PP, HARDEN TJ, CHEUNG MM: Emergence of multiple antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Andinicrob. Agents Cheinother. (1995) 39:2667–2670.
   PubMed Web of Science ®Google Scholar
• GESLIN P, BUU-HOI A, FREMAUX A, ACAR JF: Antimicrobial resistance in Streptococcus pneurnoniae an epidemiological survey in France; 1970-1990. Clin. Infect. Dis. (1992) 15:95–98.
   PubMed Web of Science ®Google Scholar
• SONG JH, YANG JW, PECK KR et al.: Spread of multidrug-resistant Streptococcus pneumoniae in South Korea. Clin. Infect. Dis. (1997) 25:747–749.
   PubMed Web of Science ®Google Scholar
• DOERN GV, PFALLER MA, KUGLER K,FREEMAN J, JONES RN: Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin. Infect. Dis. (1998) 27:764–770.
   PubMed Web of Science ®Google Scholar
• DOERN GV, BRUEGGEMANN AB, PIERCE G, HOLLEY HP, RAUCH A: Antibiotic resistance among clinical isolates of Haernophilus iniluenzae in the United States in 1994 and 1995 and detection off3-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antiinicrob. Agents Cheinother. (1997) 41:292–297.
   PubMed Web of Science ®Google Scholar
• GOLD HS, MOELLERING RC: Antimicrobial-drug resistance. N Engl. J. Med. (1996) 335:1445–1443.
   PubMed Web of Science ®Google Scholar
• •Excellent analysis of the problem of drug resistance.
   Google Scholar
• LIVERMORE DM, YUAN M: Antibiotic resistance and production of extended-spectrum13-lactamases amongst Klebsiella species from intensive care units in Europe. J. Andinicrob. Cheinother. (1996) 38:409–424.
   PubMed Web of Science ®Google Scholar
• DE GHELDRE Y, MAES N, ROST F et al: Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistance. Clin. Microbiol. (1997) 35:152–160.
   Web of Science ®Google Scholar
• RICHARD P, LE FLOCH R, CHAMOUX C, PANNIER M, ESPAZE E, RICHET H: Pseudoinonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J. Infect. Dis. (1994) 170:377–383.
   PubMed Web of Science ®Google Scholar
• TOWNER KJ: Clinical importance and antibiotic resistance of Acinetobacter spp. Med. Microbic] (1997) 46:721–746.
   PubMed Web of Science ®Google Scholar
• CHOPRA I, HODGSON J, METCALF B, POSTE G: The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antiinicrob. Agents Chemother. (1997) 41:497–503.
   PubMed Web of Science ®Google Scholar
• LEE VJ, MILLER GH, YAGISAWA M: What's new in the antibiotic pipeline. Curi: Opin. Microbiol (1999) 2:475–482.
   PubMed Web of Science ®Google Scholar
• MOELLERING RC JR.: Antibiotic resistance: lessons for the future. Clin. Infect. Dis. (1998) 27\(Suppl. 1):S135–S140
   Google Scholar
• CHOPRA I: Research and development of antibacterial agents. Curr: Opin. Microbiol (1998) 1:495–501.
   PubMed Web of Science ®Google Scholar
• BONNEFOY A, GIRARD AM, AGOURIDAS C, CHANTOT JF: Ketolides lack inducibility properties of MLSB resistance phenotype. Antimicrob. Chemother. (1997) 40:85–90.
   Web of Science ®Google Scholar
• BARRY AL, FUCHS PC, BROWN SD: Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin quinupristin-dalfopristin), a macrolide (erythromycin) and a lincosamide (clindamycin). Antimicrob. Agents Chemother. (1998) 42:945–946.
   PubMed Web of Science ®Google Scholar
• YASSIN HM, DEVER LL: Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infection. Expert Opin. Investig. Drugs (2001) 10:353–367.
   PubMed Web of Science ®Google Scholar
• CAPOBIANO JO, CAO Z, SHORTRIDGE VD, MA Z, FLAMM RK, ZHENG P: Studies of the novel ketolide ABT-773. Transport, binding to ribosomes and inhibition of protein synthesis of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2000) 44:1562–1567.
   Google Scholar
• NILIUS AM, BUI M, ALMER L et al.: Comparison of the M vitro activity of ABT-773, a novel antibacterial ketolide, with erythromycin and ciprofloxacin against respiratory pathogens. J. Antimicrob. Chemother. (1999) 44(Suppl. A):76.
   Google Scholar
• JORGENSEN JH, CRAWFORD SA, MCELMEEL ML, WHITNEY CG: Activity of the ketolide ABT-773 against recent North American isolates of Streptococcus pneumoniae. Clin. Microbiol Infect. (2000) 6\(Suppl. 1):85.
   Google Scholar
• SHINABARGER DL, MAROTTI KR, MURRAY RW et al Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. (1997) 41:2132–2136.
   PubMed Web of Science ®Google Scholar
• SWANEY SM, AOKI H, GANOZA MC, SHINABARGER DL: The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. (1998) 42:3251–3255.
   PubMed Web of Science ®Google Scholar
• RUBINSTEIN E, CAMMARATA S, OLIPHANT T, WUNDERINK R; LINEZOLID NOSOCOMIAL PNEUMONIA STUDY GROUP: Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. D AK (2001) 32(3):402–412.
   PubMed Web of Science ®Google Scholar
• GONZALES RD, SCHRECKENBERGER PC, GRAHAM MB, KELKAR S, DENBESTEN K, QUINN JP: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet (2001) 357:1179.
   PubMed Web of Science ®Google Scholar
• TSIODRAS S, GOLD HS, SAKOULAS G et al Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358:207–208.
   PubMed Web of Science ®Google Scholar
• JANSZ AR, MOUTON JW: Multi-center M vitro evaluation of linezolid compared with other antibiotics in The Netherlands. Clin. Microbiol Infect. (2000) 6\(Suppl. 1):86.
   Google Scholar
• PAWSEY SD, DALEY-YATES PT, WAJSZCZUK CP et al.: U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration. In Program and abstracts of the 1st European Congress of Chemotherapy (1996): F151.
   Google Scholar
• COCITO C, DI GIAMBATTISTA M, NYSSEN E, VANNUFFEL P: Inhibition of protein synthesis by streptogramins and related antibiotics. Antimicrob. Chemother: (1997) 39(Suppl.
   Google Scholar
• CHOPRA I: Glycyclines: third-generation tetracycline antibiotics. Carr. Opin. Pharmacol (2001) 1:464–469.
   PubMedGoogle Scholar
• CHOPRA I, ROBERTS M: Tetracycline antibiotic: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol MM. Biol. Rev (2001) 65:232–260.
   PubMed Web of Science ®Google Scholar
• PETERSEN PJ, JACOBUS NV, WEISS WJ, SUM PE, TESTA RT: In vitro and M vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother: (1999) 43:738–744.
   Google Scholar
• SOULI M, WENNERSTEN CB, ELIOPOULOS GM: In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int. I Antimicrob. Agents (1998) 10:23–30.
   PubMed Web of Science ®Google Scholar
• DALHOFF A: Pharmacodynamics of fluoroquinolones. I Antimicrob. Chemother. (1999) 43(Suppl. B):51–59.
   Google Scholar
• KIM OK, BARRETT JF, OHEMENG K: Advances in DNA gyrase inhibitors. Expert Opin. Investig. Drugs(2001) 10:199–212.
   PubMed Web of Science ®Google Scholar
• JEVONS GM, ANDREWS JM, WISE R: The tentative BSAC breakpoint of gemifloxacin, a novel fluoroquinolone. Antimicrob. Chemother: (1999) 44(Suppl. A):141.
   Google Scholar
• FELMINGHAM D, ROBBINS MJ, DENCER C, SALMAN H, MATHIAS I, RUDGWAY GL: In vitro activity of gemifloxacin against S. pneumoniae, H influenzae, M catarrhalis, L. pneumophila and Chlamydiaspp. I Antimicrob. Chemother. (1999) 44(Suppl. A):131.
   Google Scholar
• TURNIDGE J: Pharmacokinetic and pharmacodynamic profiles of the new quinolones.J. Antimicrob. Chemother. (1999) 44(Suppl. A):27.
   Google Scholar
• DI MODUGNO E, FELICI A: The renewed challenge of 13-lactams to overcome bacterial resistance. Curt: Opin. Anti-Infect. Investig. Drugs (1999) 1:26–39.
   Google Scholar
• ADACHI Y, NAGANO R, SHIBATA K, KATO Y, HASHIZUME T, MORISHIMA H: In vitro activities ifJ-111,225, J-114,870, J-114,871, novel carbapenems having potent activities against MRSA and Pseudomonas aemginosa. In: Abstracts of the 38th Intersci. Conf. Antimicrob. Agents Chemother: (1998): F–54.
   Google Scholar
• ANDES D: J-111,225. Curr. Opin. Antiinfect. Invest. Drugs(1999) 1:111–113.
   Google Scholar
• NICCOLAI D, TARSI L, THOMAS RJ: The renewed challenge of antibacterial chemotherapy. Chem. Comm. (1997) 2:2333–2342.
   Web of Science ®Google Scholar
• NICAS TI, ZECKEL ML, BRAUN DK: Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance. Trends Microbiol (1997) 5:240–249.
   PubMed Web of Science ®Google Scholar
• ARTHUR M, COURVALIN P: Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. (1993) 37:1563–1571.
   PubMed Web of Science ®Google Scholar
• GE Y, MACDONALD DL, HOLROYD KJ, THORNSBERRY C, WEXLER H, ZASLOFF M: In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. (1999) 43:782–788.
   PubMed Web of Science ®Google Scholar
• JOHANSEN C, VERHEUL A, GRAM L, GILL T, ABEE T: Protamine-induced permeabilization of cell envelopes of Gram-positive and Gram-negative bacteria. Appl. Environ. Microbiol (1997) 63:1155–1159.
   PubMed Web of Science ®Google Scholar
• HANCOCK REW, NAIR P: Cationic antimicrobial peptide antibiotics. Carr. Opin. Anti-infect. Invest. Drugs (2000) 2:140–144.
   Google Scholar
• KRENSKY AM, OKADA S, CLAYBERGER C, KUMAR J: Granulysin: a novel antimicrobial. Expert Opin. Investig. Drugs (2001) 10:321–329.
   PubMed Web of Science ®Google Scholar
• HANCOCK REW, NAIR P: Cationic antimicrobial peptide antibiotics. Curt: Opin. Anti-infect. Invest. Drugs (2000) 2:140–144.
   Google Scholar
• TALLY FP, ZECKEL M, WASILEWSKI MM et al.: Daptomycin: a novel agent for Gram-positive infections. Expert Opin. Investig. Drugs(1999) 8:1223–1238.
   PubMedGoogle Scholar
• JACOBUS NV, MCDERMOTT L, LONKS JR, BOYCE JM, SNYDMAN DR: ha vitro activity of daptomycin against resistant Gram-positive pathogens. In Abstracts of the 38th Intersci. Conf. Antimicrob. Agents Chemother. (1998): F–112.
   Google Scholar
• RYBAK MJ, HERSHBERGER E, MOLDOVAN T: Comparative in vitro activity of daptomycin versus vancomycin, linezolid, and synercid against methicillin-resistant and susceptible staphylococci, vancomycin-intermediate susceptible Staphylococcus aureus (VISA) and vancomycin-susceptible Staphylococcus aureus. In: Abstracts of the 38th Intersci. Cold: Antimicrob. Agents Chemother: (1998):C–146.
   Google Scholar
• OLIVER N, ANDREW T, SILVERMAN JA, TALLY FP: ha vitro studies on resistance to lipopeptide antibiotic daptomycin. In: Abstracts of the 38th Intersci. Conf Antimicrob. Agents Chemother. (1998): F–117.
   Google Scholar
• CANEPARI P, BOARETTI M, DEL MAE LLE0 M, SATTA G: Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob. Agents Chemother: (1990) 34:1220–1226.
   Google Scholar
• ALBORN WE JR., ALLEN NE, TRESTONDA: Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. (1991) 35:2639–2642.
   PubMed Web of Science ®Google Scholar
• SILVERMAN JA, OLIVER N, ANDREW T, LI T: Resistance studies with daptomycin. Antimicrob. Agents Chemother. (2001) 45:1799–1802.
   PubMed Web of Science ®Google Scholar
• CHAIBI EB, SIROT D, PAUL G, LABIA R:Inhibitor-resistant TEM I3-lactamases: phenotypic, genetic and biochemical characteristics. j Antimicrob. Chemother: (1999) 43:447–458.
   Google Scholar
• MAITI SN, PHILLIPS OA, MICETICH RG, LIVERMORE DM: I3-Lactamase inhibitors: agents to overcome bacterial resistance. Carr: Med. Chem. (1998) 5:441–456.
   Google Scholar
• MASUDA N, GOTOH N, ISHII C, SAKAGAWA E, OHYA S, NISHINO T: Interplay between chromosomal 13-lactamase and the MexAB-OprM efflux system in intrinsic resistance to I3-lactams in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1999) 43:400–402.
   PubMed Web of Science ®Google Scholar
• COLEMAN, K, ATHALYE, M, CLANCEY A et al: Bacterial resistance mechanisms as therapeutic targets. Antimicrob. Chemother: (1994) 33:1091–1116.
   Web of Science ®Google Scholar
• YUAN Z, TRIAS J,WHITE RJ: Deformylase as a novel antibacterial target. Drug Discov.Today(2001) 6:954–961.
   PubMed Web of Science ®Google Scholar
• THARARENSEN A, DEIBEL MR, ROHRER DC et al.: Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionally on inhibition. Bioorg. Med. Chem. Lett. (2001) 11:2053–2058.
   Web of Science ®Google Scholar
• POULSEN SM, KARLSSON M, JOHANSSON LB, VESTER B: The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Mol. Microbiol. (2001) 41:1091–1099.
   PubMed Web of Science ®Google Scholar
• CLEMENTS JM, BECKETT RP, BROWN A et al: Antibiotic activity and characterization of BB3497- a new class of peptide deformylase inhibitor. Antimicrob. Agents Chemother. (2001) 45:563–570.
   PubMed Web of Science ®Google Scholar
• GARAU J: The clinical impact of macrolideresistance in pneumococcal respiratory infections. Int. J. Antimicrob. Agents (2001) 18:(S1) 33–38.
   Google Scholar
• CAZZOLA M, MATERA MG, DONNER CF: Pharmacolkinetics and pharmacodynamics of newer oral cephalosporins: implication for treatment of community-acquired lower respiratory tract infections. Clin. Drug Invest. (1998) 16:335–346.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M: Problems and prospectives inthe antibiotic treatment of lower respiratory tract infections. Palm. Pharmacol. (1994) 7:139–152.
   Google Scholar